Online inquiry

IVTScrip™ mRNA-Anti-ERBB3, LJM716(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ10316MR)

This product GTTS-WQ10316MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets ERBB3 gene. The antibody can be applied in Breast Cancer research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001005915.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2065
UniProt ID P21860
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ERBB3, LJM716(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ10316MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5260MR IVTScrip™ mRNA-Anti-S, CB-6(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA CB-6
GTTS-WQ9565MR IVTScrip™ mRNA-Anti-EGFR&MET, JNJ-61186372(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA JNJ-61186372
GTTS-WQ14552MR IVTScrip™ mRNA-Anti-IL13&IL4, SAR156597(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA SAR156597
GTTS-WQ15684MR IVTScrip™ mRNA-Anti-VEGFA, VEGF Trap(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA VEGF Trap
GTTS-WQ3987MR IVTScrip™ mRNA-Anti-LTB&TNFSF14, BG9924(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BG9924
GTTS-WQ8145MR IVTScrip™ mRNA-Anti-CD37, HH1(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA HH1
GTTS-WQ8645MR IVTScrip™ mRNA-Anti-AXL, HuMax-AXL-ADC(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA HuMax-AXL-ADC
GTTS-WQ3982MR IVTScrip™ mRNA-Anti-LTB&TNFSF14, BG9924(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BG9924
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW